Recent News & Updates in Botox Training, Aesthetic Medicine & GLP-1 Medical Weight Management

A new clinical trial gives providers objective, measured evidence on DAO Botox® injection technique and its effect on lower-face muscle balance. The findings show why new injectors need to think beyond the patient’s stated concern to guide both the treatment and the result.

June’s clinical evidence points to a more disciplined approach to combination care: select and sequence treatment based on anatomy, evidence quality, recovery burden, and the patient’s changing trajectory. This update examines new data on skin-quality injectables, radiofrequency microneedling, and regenerative approaches to help aesthetic providers build safer, more individualized plans.

The May 2026 aesthetic medicine update covers a neurotoxin pipeline producing genuinely new options and a patient population that is outgrowing the standard consult model. Providers who act on this month’s clinical and business signals — from GLP-1 protocol updates to the growing male aesthetic market — will be better positioned heading into the second half of 2026.

April’s clinical and business signals point in the same direction: the practices growing most consistently right now are those expanding their definition of who their patient is. From menopausal skin protocols to GLP-1 consult frameworks and wellness integration strategies, this month’s update covers what to implement now and what to keep on your radar.